Targeting angiogenesis in the treatment of hepatic metastasis

Christina M. Edwards, J. Joshua Smith, Nipun Merchant, Alexander A. Parikh

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The liver is the most common site for the development of metastases from gastrointestinal malignancies. Although the only potentially curative option for patients with liver metastases is resection, only a minority are candidates. In order to increase the number of patients who may be candidates for resection, preoperative systemic chemotherapy and targeted therapy approaches have been utilized. Angiogenesis has been shown to be integral for the growth and metastasis of many tumor types including the development of liver metastases. The development of antiangiogenic approaches, particularly anti vascular endothelial growth factor (VEGF) therapy with bevacizumab, has shown great promise in the treatment of patients with liver metastases, particularly from colorectal cancer and to a lesser degree, neuroendocrine carcinoma. These approaches have allowed physicians to increase the number of patients that may be amenable for curative resection. As angiogenesis and VEGF have been shown to be important in liver hypertrophy and regeneration, however, the possible effects of anti-VEGF therapy on liver recovery may carry significant risks along with the potential benefits.

Original languageEnglish (US)
Title of host publicationCancer Metastasis - Biology and Treatment
Pages417-430
Number of pages14
Volume16
Edition1
DOIs
StatePublished - 2011
Externally publishedYes

Publication series

NameCancer Metastasis - Biology and Treatment
Number1
Volume16
ISSN (Print)15682102

Fingerprint

Neoplasm Metastasis
Liver
Vascular Endothelial Growth Factor A
Therapeutics
Neuroendocrine Carcinoma
Liver Regeneration
Hypertrophy
Colorectal Neoplasms
Neoplasms
Physicians
Drug Therapy
Growth

Keywords

  • Angiogenesis
  • Bevacizumab
  • Liver
  • Neoadjuvant
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Edwards, C. M., Smith, J. J., Merchant, N., & Parikh, A. A. (2011). Targeting angiogenesis in the treatment of hepatic metastasis. In Cancer Metastasis - Biology and Treatment (1 ed., Vol. 16, pp. 417-430). (Cancer Metastasis - Biology and Treatment; Vol. 16, No. 1). https://doi.org/10.1007/978-94-007-0292-9_15

Targeting angiogenesis in the treatment of hepatic metastasis. / Edwards, Christina M.; Smith, J. Joshua; Merchant, Nipun; Parikh, Alexander A.

Cancer Metastasis - Biology and Treatment. Vol. 16 1. ed. 2011. p. 417-430 (Cancer Metastasis - Biology and Treatment; Vol. 16, No. 1).

Research output: Chapter in Book/Report/Conference proceedingChapter

Edwards, CM, Smith, JJ, Merchant, N & Parikh, AA 2011, Targeting angiogenesis in the treatment of hepatic metastasis. in Cancer Metastasis - Biology and Treatment. 1 edn, vol. 16, Cancer Metastasis - Biology and Treatment, no. 1, vol. 16, pp. 417-430. https://doi.org/10.1007/978-94-007-0292-9_15
Edwards CM, Smith JJ, Merchant N, Parikh AA. Targeting angiogenesis in the treatment of hepatic metastasis. In Cancer Metastasis - Biology and Treatment. 1 ed. Vol. 16. 2011. p. 417-430. (Cancer Metastasis - Biology and Treatment; 1). https://doi.org/10.1007/978-94-007-0292-9_15
Edwards, Christina M. ; Smith, J. Joshua ; Merchant, Nipun ; Parikh, Alexander A. / Targeting angiogenesis in the treatment of hepatic metastasis. Cancer Metastasis - Biology and Treatment. Vol. 16 1. ed. 2011. pp. 417-430 (Cancer Metastasis - Biology and Treatment; 1).
@inbook{d490a3802f804151b129013a7420cc1b,
title = "Targeting angiogenesis in the treatment of hepatic metastasis",
abstract = "The liver is the most common site for the development of metastases from gastrointestinal malignancies. Although the only potentially curative option for patients with liver metastases is resection, only a minority are candidates. In order to increase the number of patients who may be candidates for resection, preoperative systemic chemotherapy and targeted therapy approaches have been utilized. Angiogenesis has been shown to be integral for the growth and metastasis of many tumor types including the development of liver metastases. The development of antiangiogenic approaches, particularly anti vascular endothelial growth factor (VEGF) therapy with bevacizumab, has shown great promise in the treatment of patients with liver metastases, particularly from colorectal cancer and to a lesser degree, neuroendocrine carcinoma. These approaches have allowed physicians to increase the number of patients that may be amenable for curative resection. As angiogenesis and VEGF have been shown to be important in liver hypertrophy and regeneration, however, the possible effects of anti-VEGF therapy on liver recovery may carry significant risks along with the potential benefits.",
keywords = "Angiogenesis, Bevacizumab, Liver, Neoadjuvant, VEGF",
author = "Edwards, {Christina M.} and Smith, {J. Joshua} and Nipun Merchant and Parikh, {Alexander A.}",
year = "2011",
doi = "10.1007/978-94-007-0292-9_15",
language = "English (US)",
isbn = "9789400702912",
volume = "16",
series = "Cancer Metastasis - Biology and Treatment",
number = "1",
pages = "417--430",
booktitle = "Cancer Metastasis - Biology and Treatment",
edition = "1",

}

TY - CHAP

T1 - Targeting angiogenesis in the treatment of hepatic metastasis

AU - Edwards, Christina M.

AU - Smith, J. Joshua

AU - Merchant, Nipun

AU - Parikh, Alexander A.

PY - 2011

Y1 - 2011

N2 - The liver is the most common site for the development of metastases from gastrointestinal malignancies. Although the only potentially curative option for patients with liver metastases is resection, only a minority are candidates. In order to increase the number of patients who may be candidates for resection, preoperative systemic chemotherapy and targeted therapy approaches have been utilized. Angiogenesis has been shown to be integral for the growth and metastasis of many tumor types including the development of liver metastases. The development of antiangiogenic approaches, particularly anti vascular endothelial growth factor (VEGF) therapy with bevacizumab, has shown great promise in the treatment of patients with liver metastases, particularly from colorectal cancer and to a lesser degree, neuroendocrine carcinoma. These approaches have allowed physicians to increase the number of patients that may be amenable for curative resection. As angiogenesis and VEGF have been shown to be important in liver hypertrophy and regeneration, however, the possible effects of anti-VEGF therapy on liver recovery may carry significant risks along with the potential benefits.

AB - The liver is the most common site for the development of metastases from gastrointestinal malignancies. Although the only potentially curative option for patients with liver metastases is resection, only a minority are candidates. In order to increase the number of patients who may be candidates for resection, preoperative systemic chemotherapy and targeted therapy approaches have been utilized. Angiogenesis has been shown to be integral for the growth and metastasis of many tumor types including the development of liver metastases. The development of antiangiogenic approaches, particularly anti vascular endothelial growth factor (VEGF) therapy with bevacizumab, has shown great promise in the treatment of patients with liver metastases, particularly from colorectal cancer and to a lesser degree, neuroendocrine carcinoma. These approaches have allowed physicians to increase the number of patients that may be amenable for curative resection. As angiogenesis and VEGF have been shown to be important in liver hypertrophy and regeneration, however, the possible effects of anti-VEGF therapy on liver recovery may carry significant risks along with the potential benefits.

KW - Angiogenesis

KW - Bevacizumab

KW - Liver

KW - Neoadjuvant

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84870532930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870532930&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-0292-9_15

DO - 10.1007/978-94-007-0292-9_15

M3 - Chapter

SN - 9789400702912

VL - 16

T3 - Cancer Metastasis - Biology and Treatment

SP - 417

EP - 430

BT - Cancer Metastasis - Biology and Treatment

ER -